omniture
上海药明生物技术有限公司 Wuxi Biologics

Latest News

WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL

* The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to en...

2025-06-30 19:00 3920

Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report

* Contributing to United Nations Sustainable Development Goals * Enhancing transparency and effe...

2025-04-29 18:47 2368

WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year

* Firm commitment to tackling climate change in support of United Nations Sustainable Development...

2025-04-22 16:30 4226

WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site

-          The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,...

2025-04-18 14:30 4701

WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards

SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...

2025-04-14 21:07 2684

WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025

* Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY * Adjusted...

2025-03-25 18:30 2843

WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year

* Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development ...

2025-03-21 08:30 1981

WuXi Biologics Included in S&P Global Sustainability Yearbook 2025

* Ranking in top 1% of S&P Global CSA Score * Inclusion in Global Yearbook for third consecutive...

2025-03-11 11:18 2962

WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production

-          EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysog...

2025-03-04 08:30 2156

WuXi Biologics Again Passed GMP Inspection by Japan PMDA

WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ...

2025-02-27 16:30 3407

WuXi Biologics Again Passed GMP Inspection by Japan PMDA

WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ...

2025-02-27 12:30 2304

WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year

* Ranked among the top 1% of more than 150,000 companies across 185 countries * Trusted by globa...

2025-02-18 17:00 2750

WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year

* Ranked among the top 1% of companies assessed in the pharmaceutical industry * Recognized as a ...

2025-02-10 17:00 2665

WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a lead...

2025-01-07 08:00 1922

WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year

* Named for second consecutive year named to prestigious DJSI list * Leading green biologics sol...

2025-01-02 17:30 2467

WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection

* Leading Green CRDMO Driven by Innovation for a Healthier Future * Offering End-to-end Green Bi...

2024-12-12 16:30 2296

WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development

SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...

2024-10-28 17:00 1927

WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year

HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...

2024-10-16 20:00 3882

WuXi Biologics Included in Hang Seng ESG 50 Index

HONG KONG, Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global C...

2024-09-23 17:30 2074

WuXi Biologics Reports Solid 2024 Interim Results

Revenue increased by 1.0% YoY to RMB 8,574.2 million Non-COVID revenue grew by 7.7% YoY, with non-CO...

2024-08-21 23:46 3877